Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003382 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
A Phase 1 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00003382 is a Phase 1 study that was terminated before completion, run by Gynecologic Oncology Group.
The verdict
NCT00003382, a Phase 1 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of gemcitabine and topotecan in treating patients with refractory or recurrent ovarian or fallopian tube cancer.
Interventions
- BIOLOGICAL filgrastim
- DRUG gemcitabine hydrochloride
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003382
The ClinicalTrials.gov registry entry for NCT00003382 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which filgrastim is the first listed.
NCT00003382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003382 about?
NCT00003382 is a clinical study titled "Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of gemcitabine and topotecan in tr...
What is the current status of trial NCT00003382?
This trial is currently terminated. It is a Phase 1 study. The study started on 1998-05.
What interventions are being tested in trial NCT00003382?
The interventions under investigation include: filgrastim (BIOLOGICAL), gemcitabine hydrochloride (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003382?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.